Connection
Daniel Bowles to Vascular Endothelial Growth Factor Receptor-2
This is a "connection" page, showing publications Daniel Bowles has written about Vascular Endothelial Growth Factor Receptor-2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.056 |
|
|
|
-
Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Meng X, Van Tornout JM, Conlan MG, Kang H. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res. 2023 11 14; 29(22):4555-4563.
Score: 0.056